Antibody drug-conjugates targeting the tumor vasculature: Current and future developments |
| |
Authors: | Hans-Peter Gerber Peter D Senter Iqbal S Grewal |
| |
Affiliation: | 1.Department of Pre-Clinical Therapeutics; Seattle Genetics, Inc.; Bothell, WA USA;2.Departmernt of Chemistry; Seattle Genetics, Inc.; Bothell, WA USA |
| |
Abstract: | Reducing the blood supply of tumors is one modality to combat cancer. Monoclonal antibodies are now established as a key therapeutic approach for a range of diseases. Owing to the ability of antibodies to selectively target endothelial cells within the tumor vasculature, vascular targeting programs have become a mainstay in oncology drug development. However, the antitumor activity of single agent administration of conventional anti-angiogenic compounds is limited and the improvements in patient survival are most prominent in combinations with chemotherapy. Furthermore, prolonged treatment with conventional anti-angiogenic drugs is associated with toxicity and drug resistance. These circumstances provide a strong rationale for novel approaches to enhance the efficacy of mAbs targeting tumor vasculature such as antibody-drug conjugates (ADCs). Here, we review trends in the development of ADCs targeting tumor vasculature with the aim of informing future research and development of this class of therapeutics.Key words: tumor, vasculature, immunotherapy, antibody-drug conjugates, monoclonal antibody, cancer, angiogenesis |
| |
Keywords: | |
|
|